almagate has been researched along with Branch Vein Occlusion in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (26.32) | 29.6817 |
| 2010's | 13 (68.42) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Hara, H; Nakamura, S | 1 |
| Li, M; Qian, T; Wan, Y; Xu, X; Zhao, M | 1 |
| Choovuthayakorn, J; Ittipunkul, N; Kunavisarut, P; Pathanapitoon, K; Patikulsila, D; Saenpen, N; Watanachai, N | 1 |
| Braithwaite, T; Greenberg, PB; Lindsley, K; Nanji, AA | 1 |
| Huang, P; Song, Z; Sun, X | 1 |
| Bakri, SJ; Ehlers, JP; Ho, AC; Kim, SJ; Schoenberger, SD; Thorne, JE; Yeh, S | 1 |
| Ehrlich, R; Harris, A; Hussain, RM; Prall, R; Siesky, B; Yung, CW | 1 |
| Angulo Bocco, MC; Coscas, G; Glacet-Bernard, A; Soubrane, G; Zourdani, A | 1 |
| Adamis, AP; Altaweel, MM; Buggage, RR; Cunningham, ET; Goldbaum, M; Guyer, DR; Katz, B; Wells, JA; Wroblewski, JJ | 1 |
| Díaz-Llopis, M; Francés, E; Gallego-Pinazo, R; Gómez-Maestra, M; López-Lizcano, R; Udaondo, P | 1 |
| Díaz-Llopis, M; Francés, E; Gallego-Pinazo, R; Gómez, MJ; López, R | 1 |
| Gonzales, CR; Wells, JA; Wroblewski, JJ | 1 |
| Cohen, SY; Nghiem-Buffet, S | 1 |
| Chan, C; Koo, S; Wong, I | 1 |
| Agostini, H; Bertram, B; Feltgen, N; Hansen, L; Hoerauf, H; Jaissle, GB; Pielen, A; Stahl, A | 1 |
| Braithwaite, T; Greenberg, PB; Nanji, AA | 1 |
| Grabska-Liberek, I; Jamrozy-Witkowska, A; Jankowska-Lech, I; Kowalska, K; Nowosielska, A; Terelak-Borys, B | 1 |
| Bodaghi, B; Cochereau, I; Dumarcet, N; Goebel, F; Hajjar, J; Korobelnik, JF | 1 |
| Campochiaro, PA | 1 |
8 review(s) available for almagate and Branch Vein Occlusion
| Article | Year |
|---|---|
[Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Diabetic Retinopathy; Drug Development; Humans; Macular Degeneration; Mice; Molecular Targeted Therapy; Neovascularization, Pathologic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retina; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2021 |
Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.
Topics: Adrenal Cortex Hormones; Aptamers, Nucleotide; Dexamethasone; Humans; Intraocular Pressure; Intravitreal Injections; Macular Edema; Network Meta-Analysis; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Risk Assessment; Treatment Outcome; Triamcinolone; Vascular Endothelial Growth Factor A | 2018 |
Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2014 |
Therapies for macular edema associated with central retinal vein occlusion: a report by the American Academy of Ophthalmology.
Topics: Academies and Institutes; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Databases, Factual; Drug Therapy, Combination; Glucocorticoids; Humans; Intravitreal Injections; Laser Coagulation; Macular Edema; Ophthalmology; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Technology Assessment, Biomedical; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity | 2015 |
[Retinal vein occlusion: anti-VEGF treatments].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood-Retinal Barrier; Clinical Trials as Topic; Humans; Macular Edema; Prospective Studies; Ranibizumab; Retinal Vein Occlusion; Retrospective Studies; Treatment Outcome; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A; Visual Acuity | 2009 |
[Intravitreal drug therapy for retinal vein occlusion--pathophysiological mechanisms and routinely used drugs].
Topics: Adrenal Cortex Hormones; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Blood Flow Velocity; Cell Division; Combined Modality Therapy; Dexamethasone; Endothelium, Vascular; Erythropoietin; Hemodilution; Humans; Intravitreal Injections; Laser Coagulation; Long-Term Care; Papilledema; Prognosis; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Artery; Retinal Vein; Retinal Vein Occlusion; Triamcinolone Acetonide; Vascular Endothelial Growth Factor A | 2010 |
Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Humans; Macular Edema; Randomized Controlled Trials as Topic; Ranibizumab; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2010 |
Anti-vascular endothelial growth factor treatment for retinal vein occlusions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A | 2012 |
3 trial(s) available for almagate and Branch Vein Occlusion
| Article | Year |
|---|---|
Pegaptanib sodium for macular edema secondary to central retinal vein occlusion.
Topics: Angiogenesis Inhibitors; Aptamers, Nucleotide; Double-Blind Method; Female; Fluorescein Angiography; Humans; Injections; Macular Edema; Male; Middle Aged; Retinal Vein Occlusion; Tonometry, Ocular; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2009 |
[Initial and unique treatment of macular edema due to branch retinal vein occlusion with antiangiogenic agents. A comparative pilot study].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Follow-Up Studies; Humans; Macular Edema; Pilot Projects; Ranibizumab; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity | 2009 |
Pegaptanib sodium for macular edema secondary to branch retinal vein occlusion.
Topics: Aged; Aged, 80 and over; Aptamers, Nucleotide; Female; Humans; Injections; Macular Edema; Male; Middle Aged; Prospective Studies; Retina; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
8 other study(ies) available for almagate and Branch Vein Occlusion
| Article | Year |
|---|---|
The use of intravitreal anti-vascular endothelial growth factor injection and its complications in Chiang Mai University Hospital.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Child; Child, Preschool; Diabetic Retinopathy; Female; Hospitals, University; Humans; Infant; Intravitreal Injections; Macular Degeneration; Male; Middle Aged; Ranibizumab; Retinal Vein Occlusion; Retrospective Studies; Thailand; Vascular Endothelial Growth Factor A; Young Adult | 2013 |
Predictors of anti-vascular endothelial growth factor treatment responses in macular edema following central vein occlusion.
Topics: Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Humans; Macular Edema; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retinal Vein Occlusion; Vascular Endothelial Growth Factor A; Visual Acuity | 2014 |
The effect of pegaptanib (Macugen(®) ) injection on retinal and retrobulbar blood flow in retinal Ischaemic diseases.
Topics: Adult; Aged; Angiogenesis Inhibitors; Aptamers, Nucleotide; Blood Flow Velocity; Diabetic Retinopathy; Female; Humans; Injections, Intraocular; Ischemia; Laser-Doppler Flowmetry; Macular Edema; Male; Middle Aged; Prospective Studies; Retinal Artery; Retinal Vein Occlusion; Ultrasonography, Doppler, Color; Vascular Endothelial Growth Factor A | 2015 |
[Intravitreous injection: retrospective study on 2028 injections and their side effects].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Cataract; Diabetic Retinopathy; Endophthalmitis; Epiretinal Membrane; Humans; Injections; Macular Degeneration; Macular Edema; Ocular Hypertension; Ranibizumab; Retinal Detachment; Retinal Perforations; Retinal Vein Occlusion; Retrospective Studies; Risk Assessment; Triamcinolone Acetonide; Vitreous Body; Vitreous Hemorrhage | 2008 |
[Macular thickness might be a recurrence probability predictor in macular edema due to retinal vein occlusions treated with repeated intravitreal injections of antiangiogenics].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Drug Monitoring; Humans; Injections; Macula Lutea; Macular Edema; Prognosis; Ranibizumab; Recurrence; Retinal Vein Occlusion; Vitreous Body | 2009 |
Pegaptanib for branch retinal vein occlusion.
Topics: Aptamers, Nucleotide; Humans; Injections; Macular Edema; Retina; Retinal Vein Occlusion; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitreous Body | 2010 |
[Complications of intravitreal injections--own experience].
Topics: Aged; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Aptamers, Nucleotide; Bevacizumab; Conjunctival Diseases; Diabetic Retinopathy; Endophthalmitis; Eye Diseases; Eye Hemorrhage; Female; Follow-Up Studies; Glucocorticoids; Humans; Inflammation; Intravitreal Injections; Iris Diseases; Macular Degeneration; Macular Edema; Male; Middle Aged; Ocular Hypertension; Poland; Ranibizumab; Retinal Diseases; Retinal Vein Occlusion; Retrospective Studies; Risk Factors; Triamcinolone Acetonide; Visual Acuity | 2011 |
[Intravitreal injections: AFSSAPS guide to good practice].
Topics: Aptamers, Nucleotide; Diabetic Retinopathy; Endophthalmitis; France; Humans; Intravitreal Injections; Macular Degeneration; Ophthalmologic Surgical Procedures; Postoperative Complications; Practice Guidelines as Topic; Retinal Diseases; Retinal Vein Occlusion; Societies, Medical | 2012 |